The association of fecal calprotectin and respiratory exacerbation in cystic fibrosis patients.
Farid ImanzadehFatemeh KeramiMaryam HassanzadAmirhossein HosseiniMahmoud HajipourGhamartaj KhanbabaeeNaghi DaraKatayoun KhatamiNazanin FarahbakhshAliakbar SayyariPublished in: BMC gastroenterology (2022)
Our findings revealed that fecal calprotectin modifications are associated with CF pulmonary exacerbations and antibiotic treatment could reduce calprotectin levels. Therefore, the fecal calprotectin level could be considered as a diagnostic tool and an index to follow the response to treatment in CF pulmonary exacerbations.
Keyphrases
- cystic fibrosis
- chronic obstructive pulmonary disease
- pseudomonas aeruginosa
- lung function
- disease activity
- pulmonary hypertension
- end stage renal disease
- chronic kidney disease
- ejection fraction
- newly diagnosed
- systemic lupus erythematosus
- single cell
- combination therapy
- peritoneal dialysis
- replacement therapy
- smoking cessation
- patient reported outcomes